Patent Application
20140329874
The present invention is directed to a method of treating tissue trauma (such as damage from solar or ultraviolet radiation, wounds, and burns) by administration of an alpha adrenergic agonist (such as oxymetazoline hydrochloride).
It has been recognized that alpha-adrenergic agonists are useful for treating or preventing skin redness in conditions including rosacea, acne, acute sunburn and chronic sun damage. The effectiveness of alpha-adrenergic agonists is due to their action on vascular smooth muscle that results in constriction of cutaneous blood vessels. The sympathetic nervous system mediates peripheral vasoconstriction via activation of both α1- and α2-adrenergic receptors on vascular smooth muscle. Knockout mice studies have demonstrated that either the α2A- or the α2C-adrenergic receptors mediate cutaneous vasoconstriction in the tail, depending on the air temperature (Chotani, Flavahan et al. 2000), and that α1-adrenergic receptors also play an important role in peripheral vasoconstriction (Duka, Gavras et al. 2000). In human subjects with reduced sympathetic activity, the mixed α2/α1 agonist clonidine or the α2-selective agonist dexmedetomidine reduced finger blood flow (Talke, Lobo et al. 2001; Talke, Lobo et al. 2003).
The present invention provides a method of treating tissue trauma in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist.
In another aspect, present invention provides a method for treating/alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a patient in need thereof, which comprises administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist.
While investigating the reduction of erythema by the alpha-adrenergic agonist oxymetazoline hydrochloride in a UVB-induced sunburn model, a surprising utility in addition to reduction of erythema was observed. It was surprisingly found that oxymetazoline hydrochloride also promoted skin healing following tissue injury. Exposure of hairless mice to UVB irradiation results in a rapid sunburn-like response characterized by erythema, cutaneous blood vessel dilation, tactile hypersensitivity and inflammation peaking within 2-4 hr. The burn is severe enough to result in subsequent tissue damage characterized by epidermal necrosis with separation of the epidermis from the dermis and reactive changes such as adaptive epidermal hyperplasia at 48 hr.
Accordingly, the present invention provides a method of treating tissue trauma in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist.
In one embodiment of the invention, the tissue trauma is selected from the group consisting of: damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, erosions, and ulcers.
In another embodiment, the tissue trauma is damage from ultraviolet radiation, wherein the ultraviolet radiation is ultraviolet B (UVB) radiation.
In another embodiment, the tissue trauma is a burn, that is caused by a chemical, heat, or solar radiation.
In another embodiment, the tissue trauma is a burn that is severe enough to result in subsequent tissue damage characterized by at least one condition selected from the group consisting of epidermal necrosis, separation of the epidermis from the dermis and adaptive healing response, such as epidermal proliferation and hyperplasia.
In another embodiment, the tissue trauma is an ulcer, such as diabetic or pressure ulcer.
In another embodiment, the treatment of the tissue trauma results in (a) the reduction of severity, (b) prevention of development, or (c) more rapid reepithelialization and closure of open wounds, blisters, excoriations, erosions or ulcers.
In another embodiment, the treatment of tissue trauma results in the enhancement of the healing of the tissue trauma.
In another embodiment, the treatment of the tissue trauma results in the prevention or minimized formation of fine line scars, hypertrophic scars and keloids.
In another embodiment, the tissue area is selected from the group consisting of corneal epithelium, skin, and mucous membranes (such as mouth, those in the gastrointestinal tract, and rectal and vaginal mucosa).
As set forth above, in another aspect, the present invention provides a method for alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a patient in need thereof, which comprises treating said patient with a pharmaceutical composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist. Such procedures include dermal filler injections, neurotoxin injections, Botulinum toxin injections, laser procedures, breast augmentations, breast lifts, breast reductions, face lifts, tummy tucks.
In another embodiment, the alpha adrenergic agonist may be administered in combination with an anesthetic.
The α-adrenergic receptor agonists of the present invention include any α-adrenergic receptor agonist known to skilled artisans. In some aspects, an α-adrenergic receptor agonist can be an α-adrenergic receptor agonist selective for α1-adrenergic receptors, an α-adrenergic receptor agonist selective for α2-adrenergic receptors, or an α-adrenergic receptor agonist non-selective for either α1 or α2-adrenergic receptors.
As used herein, a selective α1-adrenergic receptor agonist is an agonist for which the EC50 with respect to an α1-adrenergic receptor is less than the EC50 with respect to an α2-adrenergic receptor, while a selective α2-adrenergic receptor agonist is an agonist for which the EC50 with respect to an α2-adrenergic receptor is less than the EC50 with respect to an α1-adrenergic receptor, wherein the EC50 for an agonist is defined as the molar concentration of the agonist which produces 50% of the maximum possible response of a receptor to that agonist.
Some non-limiting examples of α-adrenergic receptor agonists which can be used in the present compositions and methods include: apraclonidine, brimonidine, clonidine, dexmedetomidine, dopamine, I-dobutamine, ephedrine, epinephrine, epinine (N-methyl-dopamine), ethylnorepinephrine, guanabenz, guanfacine, levarterenol, lofexidine, mephentermine, metaraminol, methoxamine, α-methyldopa, α-methylnorepinephrine, methylphenidate, mivazerol, mitodrine, moxonidine, naphazoline, norepinephrine, norphenylephrine, oxymetazoline, pemolinepropylhexedrine, phenylephrine, phenylpropanolamine, propylhexedrine, tetrahydrozoline, tizanidine, xylometazoline, (8-bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (8-bromo-quinoxalin-5-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (5-bromo-3-methyl-quinoxalin-6-yl)-(4,5-dihydro-1 H-imidazol-2-yl)-amine, (5-bromo-2-methoxy-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, (4,5-dihydro-1H-imidazol-2-yl)-(8-methyl-quinoxalin-6-yl)-amine, and (4,5-dihydro-1H-imidazol-2-yl)-quinoxalin-5-yl-amine.
Compositions of the present teachings include one or more α-adrenergic receptor agonists, prodrugs thereof, pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof and combinations thereof, such as those described in U.S. Pat. No. 7,439,241, which are incorporated herein by reference.
The alpha agonists of the present invention can form salts which are also within the scope of this invention. Reference to an alpha agonist herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when an alpha agonist contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the alpha agonists may be formed, for example, by reacting such an agonist with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
In another embodiment, the alpha adrenergic agonist of the present invention is selected from the group consisting of oxymetazoline, xylometazoline, tetrahydrozoline, naphazoline, brimonidine, clonidine, phenylephrine, methoxamine, mephentermine, metaraminol, desglymidodrine, and midodrine; or a pharmaceutically acceptable salt thereof.
In another embodiment, the pharmaceutically acceptable salts of oxymetazoline, xylometazoline, tetrahydrozoline, naphazoline, brimonidine, clonidine, phenylephrine, methoxamine, mephentermine, and metaraminol are respectively selected group consisting of oxymetazoline hydrochloride, xylometazoline hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, brimonidine tartrate, chlonidine hydrochloride, phenylephrine hydrochloride, methoxamine hydrochloride, mephentermine sulfate, and metaraminol bitartrate.
In another embodiment, the alpha adrenergic agonist of the present invention comprises a compound with an imidazoline structure.
In another embodiment, the compound with the imidazoline structure is selected from the group consisting of oxymetazoline, xylometazoline, tetrahydrazaline, naphazoline, brimonidine, and clonidine; or a pharmaceutically acceptable salt thereof.
In an especially preferred embodiment, the alpha adrenergic agonist of the present invention is oxymetazoline hydrochloride, having the structure:
The alpha adrenoceptor agonist of the present invention can be used in amounts of about 0.01% up to about 30%, and in one embodiment about 0.001% up to about 3%, and in one embodiment from about 0.01% up to about 30%, and in one embodiment from about 0.1% up to about 10% by weight based on the total weight of the composition. One alpha agonist or a combination or a combination of two or more agonists can be used. The alpha agonists can be used as the sole active agent, or the composition can comprising additional active agents having different functions as set forth below.
The composition of the present invention can further comprise a pharmaceutically/dermatologically acceptable carrier or vehicle. The term “pharmacologically/dermatologically acceptable carriers”, as used herein, means that the carrier is suitable for topical application to tissue area, has good aesthetic properties, is compatible with the active agents of the present invention and any other components, and will not cause any untoward safety or toxicity concerns. The carrier can be in a wide variety of forms. For example, emulsion carriers, including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicon emulsions, are useful herein. As will be understood by the skilled artisan, a given component will distribute primarily into either the water or oil/silicon phase, depending on the water solubility/dispersibility of the component in the composition. A safe and effective amount of carrier is from about 50% to about 99.999%, and in one embodiment from about 70% to about 99.99%.
The carrier or vehicle of the invention will have dramatic effects on the concentrations of the active ingredients selected. The preferred embodiments employ active ingredients in amounts effective to achieve clinical efficacy without causing systemic side effects.
The compositions according to the invention may comprise all pharmaceutical forms normally utilized for the topical route of administration and known to practitioners of this art including solutions, gels, lotions creams, ointments, foams, mousses, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof. The subject compositions may also be formulated as solid preparations constituting soaps or cleansing bars. These compositions are formulated according to conventional techniques.
In another embodiment, the affected tissue area is the skin, and the topical administration involves rubbing the composition onto the tissue area, applying the composition to the tissue area through a dermal patch, or injecting the composition into the epidermis via a micro-injector.
The composition, if desired, can contain various known bases such as excipients, binders, lubricants, and disintegrants. If desired, it can also contain oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extracts, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, pharmaceutically effective components such as vitamins, hormones, amino acids, surfactants, colorants, dyes, pigments, fragrances, odor absorbers, antiseptics, preservatives, bactericides, humectants, thickeners, solvents, fillers, antioxidants, sequestering agents, sunscreens, or any other known components and additives as long as the effects of the present invention are not impaired.
Examples of suitable oils includes mineral oils, plant oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others. Fatty alcohols, fatty acids such as stearic acid and waxes such as paraffin wax, carnauba wax or beeswax may also be used as fats. The composition may also contain emulsifying agents such as glyceryl stearate, solvents such as lower alcohols including ethanol, isopropanol, and propylene glycol, hydrophilic gelling agents including carboxyvinyl polymers or acrylic copolymers, polyacrylamides, polysaccharides, lipophilic gelling agents or fatty acid metal salts among others, hydrophilic acting agents such as amino acids, sugars, starch or urea, lipophilic active agents such as retinol or tocopherol.
Other embodiments of the present invention combine one or more adrenoceptor agonist with other active agents destined, in particular, for treating the tissue trauma with numerous other skin complaints, conditions and afflictions. Examples of these agents include:
In another embodiment, the composition of the present invention further comprises at least one ingredient selected from the group consisting of water, a solvent, a preservative, a surfactant, a gelling agent, and a pH balancer. The compositions may contain antimicrobial preservatives in some embodiments. In several embodiments, antimicrobial preservatives include, but are not limited to, methylparaben, propylparaben, benzyl alcohol, ethylhexylglycerin, potassium sorbate, phenoxyethanol, EDTA, grapefruit seed extract, tea tree oil, sodium benzoate, dehydroacetic acid, and combinations thereof. In some embodiments, anti-fungal preservatives are used alone or in combination with anti-bacterial preservatives.
Suitable gelling agents known in the art, including those used in the two-phase or single-phase gel systems, can be used in the present invention. Some examples of suitable gelling agents are disclosed in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1517-1518 (Alfonso R. Gennaro ed. 19th ed. 1995), which is hereby incorporated herein by reference. The gelling agents used in embodiments of the present invention, include, but are not limited to, one or more hydrophilic and hydroalcoholic gelling agents used in the cosmetic and pharmaceutical industries. Suitable hydroalcoholic gelling agents include “CARBOPOL®” (B.F. Goodrich, Cleveland, Ohio), “HYPAN®” (Kingston Technologies, Dayton, N.J.), “NATROSOL®” (Aqualon, Wilmington, Del.), “KLUCEL®” (Aqualon, Wilmington, Del.), or “STABILEZE®” (ISP Technologies, Wayne, N.J.).
A xenon arc lamp (Newport Corp, USA) was used as a source of UVB. SKH1 hairless mice, lying on their stomachs with their left sides covered, were exposed to 120 mJ/cm2 UVB radiation. Regions of back skin were treated topically with oxymetazoline hydrochloride 0.5% gel at 20 min, 4 hr or 8 hr post-UVB. An additional group had the vehicle applied topically at 20 min post UVB exposure. Erythema on the exposed and unexposed back was measured using a chromameter (Konica Minolta) at 2 and 4 hr post-UVB exposure. Skin samples were collected 48 hr following UVB exposure and examined histologically to assess the extent of injury.
UVB exposure resulted in a 28% increase in erythema that peaked by 2 hr post-UVB exposure. Application of 0.5% oxymetazoline 20 minutes following UVB exposure to the back skin almost completely inhibited the erythema (p<0.001) at the 2 hr timepoint, but there was no inhibition of the erythema at 4 hr post-UVB exposure.
Histological examination at 48 hr showed that application of 0.5% oxymetazoline 20 minutes following UVB exposure to the back skin slightly improved the outcome of healing compared to concurrent vehicle controls, but healing was within the range of historical vehicle controls; therefore the significance of this slight improvement with application at 20 minutes was unknown.
Application of 0.5% oxymetazoline 4 or 8 hours following UVB exposure to the back skin improved the outcome of healing compared to both concurrent vehicle controls, and historical vehicle controls. Improved healing consisted of a shift toward adaptive epidermal hyperplasia and a reduction of epidermal necrosis, and less separation of the epidermis from underlying dermis.
The overall epidermal healing was fair to good in 33% of mice treated with 0.5% oxymetazoline at 20 minutes, 50% of mice treated at 4 hours, and 67% of mice treated at 8 hours post UVB exposure, as compared to 0% of vehicle treated mice. Therefore this study shows that treatment with 0.5% oxymetazoline topically 4-8 hours following UVB exposure improves the healing of UVB exposed epidermis. Since oxymetazoline has a very strong effect on erythema, but not on healing, in the first 2 hrs post-UVB exposure, the data also demonstrate that the enhanced healing stimulated by oxymetazoline is distinct from its vasoconstrictive actions to reduce erythema.
In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that the same are illustrative and in no ways limitative.
The following formulation of oxymetazoline was used:
The vehicle used for the purposes of testing the formulation comprises all of the above ingredients in the above table (with the same relative amounts of each, made up to 100% with purified water) with the exception of oxymetazoline hydrochloride.
One of many functions of the skin is to provide a protective barrier for underlying soft tissues. When the skin is injured and is no longer providing this function, this can result in many detrimental sequelae, such as dehydration, and introduction of infection. Therefore, when the skin is injured, it must adapt quickly and heal itself, through many interacting physiologic processes. In this study, the overall healing score given 48 hours following the injury was a measure of the overall effectiveness of this physiologic response to the UVB injury. The application of 0.5% oxymetazoline hydrochloride at 4 or 8 hours post UVB exposure resulted in a more positive outcome as seen at 48 hours following injury for many individuals; application of 0.5% oxymetazoline hydrochloride at 20 minutes post UVB exposure potentially improved the outcome at 48 hours for a few individuals. Group size: n=5 for vehicle group, and n=6 for all 0.5% Oxymetazoline groups.
The epidermis is the outermost layer of the skin in contact with the environment and crucial to the overall health and barrier function of the skin. When the epidermis becomes necrotic, it can begin to separate from the underlying dermis, and thus its function has been lost. An adequate physiologic response to injury should either prevent epidermal necrosis in the first place, and/or to promote rapid epidermal proliferation to cover any defects that may result. The epidermal separation score given 48 hours following injury indicated how much dermis was exposed as a result of failure of the skin to either prevent epidermal loss, and/or to replace lost epidermis via epidermal proliferation. The application of 0.5% oxymetazoline hydrochloride at 20 minutes, 4 hours, or 8 hours post UVB exposure, reduced the occurrence and/or severity of epidermal separation seen at 48 hours following UVB exposure for most individuals. Group size: n=5 for vehicle group, and n=6 for all 0.5% oxymetazoline hydrochloride groups.
Following an injury to skin severe enough to potentially result in epidermal loss, the healing epidermis begins to proliferate and first spreads out in a thin attenuated layer to cover any defects, then becomes hyperplastic as healing progresses. Thus in this case, 48 hours following the injury, the presence of epidermal hyperplasia indicated more advanced and effective progression of the adaptive healing response. The application of 0.5% oxymetazoline hydrochloride, especially when applied 8 hours following the injury, resulted in more individuals who had progressed to advanced healing by 48 hours post injury. Group size: n=5 for vehicle group, and n=6 for all 0.5% oxymetazoline hydrochloride groups.
Each and every reference disclosed in the specification, whether non-patent (e.g., scientific, journal references) or patent (e.g., granted patents or published patent applications) is incorporated herein by reference in its entirety for all purposes.
The foregoing descriptions details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. It should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.
This application claims the benefit of U.S. Application Ser. No. 61/819,927, filed on May 6, 2013, which is incorporated by reference herein in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61819927 | May 2013 | US |
